REGENXBIO Inc.

As of June 30, 2026, REGENXBIO, Inc. carries a market capitalization of 562.22M, placing it among publicly traded companies globally. Its enterprise value stands at 530.22M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

REGENXBIO, Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, REGENXBIO, Inc. has 54.16M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.55, and the price-to-book ratio stands at 8.95.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 530.22M versus a market cap of 562.22M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, REGENXBIO, Inc. maintains a current ratio of 2.86, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 96.08, indicating elevated leverage, while an interest coverage ratio of -3.55 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, REGENXBIO, Inc. posted a negative return on equity (ROE) of -137.63, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -40.60, reflecting losses generated across the asset base. The company generates approximately 416,709.67 in revenue per employee across its workforce of 366.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, REGENXBIO, Inc.'s stock has declined approximately 40.50% over the past 52 weeks. The 50-day moving average sits at 7.38, while the 200-day moving average is 8.10.

Over the twelve months ended June 30, 2026, REGENXBIO, Inc. generated 152.72M in revenue and converted that into -171.94M in net income, yielding earnings per share of -3.29. EBITDA reached -130.22M, while operating income came in at -143.68M.

As of June 30, 2026, REGENXBIO, Inc. holds 92.36M in cash and equivalents against 60.35M in total debt, resulting in a net debt position of -31.94M. Total book value stands at 62.82M, with working capital of 134.39M providing operational flexibility.

REGENXBIO, Inc. produced -215.91M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.62M in capital expenditures, free cash flow totaled -218.53M - equivalent to -4.19 per share.

Over the twelve months ended June 30, 2026, REGENXBIO, Inc. posted a gross margin of 86.38, reflecting its pricing power and cost economics. The operating margin of -94.08 and net profit margin of -112.58 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -40.32: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.98, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to REGENXBIO, Inc. shareholders.

As of June 30, 2026, REGENXBIO, Inc. has an Altman Z-Score of -3.57, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.